These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38275945)

  • 1. Impact of Protease Inhibitor-Based Highly Active Antiretroviral Therapy on Fetal Subcutaneous Fat Tissue in HIV-Pregnant Women in a Middle-Income Country.
    Borboa-Olivares H; Estrada-Gutierrez G; Martinez-Portilla RJ; Espino-Y-Sosa S; Flores-Pliego A; Espejel-Nuñez A; Camacho-Arroyo I; Solis-Paredes JM; Villafan-Bernal JR; Torres-Torres J
    Viruses; 2023 Dec; 16(1):. PubMed ID: 38275945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy.
    Senise JF; Castelo A; Martínez M
    AIDS Rev; 2011; 13(4):198-213. PubMed ID: 21975356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of antiretroviral therapy on pregnancy outcome in HIV-1 positive women.
    Kowalska A; Niemiec T; El Midaoui A; Burkacka E
    Med Wieku Rozwoj; 2003; 7(4 Pt 1):459-68. PubMed ID: 15010556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.
    Guaraldi G; Zona S; Orlando G; Carli F; Stentarelli C; Luzi K; Garlassi E; Menozzi M; Bagni P; Adorni F
    Clin Drug Investig; 2011 Nov; 31(11):759-67. PubMed ID: 21919542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with HIV RNA levels in pregnant women on non-suppressive highly active antiretroviral therapy at conception.
    European Collaborative Study
    Antivir Ther; 2010; 15(1):41-9. PubMed ID: 20167990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy.
    Powis KM; Kitch D; Ogwu A; Hughes MD; Lockman S; Leidner J; van Widenfelt E; Moffat C; Moyo S; Makhema J; Essex M; Shapiro RL
    J Infect Dis; 2011 Aug; 204(4):506-14. PubMed ID: 21791651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Previous antiretroviral therapy for prevention of mother-to-child transmission of HIV does not hamper the initial response to PI-based multitherapy during subsequent pregnancy.
    Briand N; Mandelbrot L; Blanche S; Tubiana R; Faye A; Dollfus C; Le Chenadec J; Benhammou V; Rouzioux C; Warszawski J;
    J Acquir Immune Defic Syndr; 2011 Jun; 57(2):126-35. PubMed ID: 21436712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated Levels of Estradiol in Human Immunodeficiency Virus-Infected Pregnant Women on Protease Inhibitor-Based Regimens.
    Balogun KA; Guzman Lenis MS; Papp E; Loutfy M; Yudin MH; MacGillivray J; Walmsley SL; Silverman M; Serghides L
    Clin Infect Dis; 2018 Jan; 66(3):420-427. PubMed ID: 29020282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy.
    Chaparro J; Reeds DN; Wen W; Xueping E; Klein S; Semenkovich CF; Bae KT; Quirk EK; Powderly WG; Yarasheski KE; Li E
    Metabolism; 2005 May; 54(5):561-7. PubMed ID: 15877283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of highly active antiretroviral therapy on obstetric conditions: A review.
    Sebitloane HM; Moodley D
    Eur J Obstet Gynecol Reprod Biol; 2017 Mar; 210():126-131. PubMed ID: 28013100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of maternal HIV status and treatment duration on body composition of HIV-exposed and HIV-unexposed preterm, very and extremely low-birthweight infants.
    Strydom K; Nel DG; Dhansay MA; Van Niekerk E
    Paediatr Int Child Health; 2018 Aug; 38(3):163-174. PubMed ID: 29790827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women.
    Grosch-Woerner I; Puch K; Maier RF; Niehues T; Notheis G; Patel D; Casteleyn S; Feiterna-Sperling C; Groeger S; Zaknun D;
    HIV Med; 2008 Jan; 9(1):6-13. PubMed ID: 18199167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
    Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    Siegfried N; van der Merwe L; Brocklehurst P; Sint TT
    Cochrane Database Syst Rev; 2011 Jul; (7):CD003510. PubMed ID: 21735394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern?
    Thorne C; Newell ML
    Drug Saf; 2007; 30(3):203-13. PubMed ID: 17343429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women.
    ; Patel D; Cortina-Borja M; Thorne C; Newell ML
    Clin Infect Dis; 2007 Jun; 44(12):1647-56. PubMed ID: 17516411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    Volmink J; Siegfried NL; van der Merwe L; Brocklehurst P
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003510. PubMed ID: 17253490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.
    Rakotoambinina B; Médioni J; Rabian C; Jubault V; Jais JP; Viard JP
    J Acquir Immune Defic Syndr; 2001 Aug; 27(5):443-9. PubMed ID: 11511820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse fetal and infant outcomes among HIV-infected women who received either nonnucleoside reverse transcriptase inhibitor-based or protease inhibitor-based antiretroviral therapy for prevention of mother-to-child transmission.
    Masaba R; Borkowf CB; Girde S; Zeh C; Ndivo R; Nyang'au I; Achola K; Thomas TK; Lecher SL
    AIDS; 2018 Jul; 32(12):1625-1632. PubMed ID: 30001243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perinatal outcomes, mitochondrial toxicity and apoptosis in HIV-treated pregnant women and in-utero-exposed newborn.
    Hernàndez S; Morén C; López M; Coll O; Cardellach F; Gratacós E; Miró O; Garrabou G
    AIDS; 2012 Feb; 26(4):419-28. PubMed ID: 22156962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.